Precigen, Inc. (PGEN)
4.27
+0.11
(+2.64%)
USD |
NASDAQ |
Nov 20, 10:10
Precigen Cash from Operations (Quarterly) : 11.88M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 11.88M |
| June 30, 2026 | -17.81M |
| March 31, 2026 | -43.83M |
| December 31, 2025 | -23.46M |
| September 30, 2025 | -29.07M |
| June 30, 2025 | -18.98M |
| March 31, 2025 | -16.32M |
| December 31, 2024 | -8.243M |
| September 30, 2024 | -22.73M |
| June 30, 2024 | -23.11M |
| March 31, 2024 | -14.09M |
| December 31, 2023 | -15.77M |
| September 30, 2023 | -17.01M |
| June 30, 2023 | -15.77M |
| March 31, 2023 | -18.39M |
| December 31, 2022 | -15.40M |
| September 30, 2022 | -23.81M |
| June 30, 2022 | -7.053M |
| March 31, 2022 | -18.78M |
| December 31, 2021 | -14.59M |
| September 30, 2021 | -17.02M |
| June 30, 2021 | -7.776M |
| March 31, 2021 | -16.38M |
| December 31, 2020 | -16.47M |
| September 30, 2020 | -19.00M |
| Date | Value |
|---|---|
| June 30, 2020 | -13.80M |
| March 31, 2020 | -27.74M |
| December 31, 2019 | -32.14M |
| September 30, 2019 | -27.15M |
| June 30, 2019 | -33.40M |
| March 31, 2019 | -43.23M |
| December 31, 2018 | -37.36M |
| September 30, 2018 | -28.82M |
| June 30, 2018 | -28.17M |
| March 31, 2018 | -29.89M |
| December 31, 2017 | -33.88M |
| September 30, 2017 | -22.01M |
| June 30, 2017 | -23.56M |
| March 31, 2017 | -24.69M |
| December 31, 2016 | -24.20M |
| September 30, 2016 | -8.744M |
| June 30, 2016 | -12.44M |
| March 31, 2016 | -3.609M |
| December 31, 2015 | 12.33M |
| September 30, 2015 | 52.90M |
| June 30, 2015 | -16.52M |
| March 31, 2015 | -13.04M |
| December 31, 2014 | -9.05M |
| September 30, 2014 | -6.637M |
| June 30, 2014 | -13.65M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 8.377M |
| Aldeyra Therapeutics, Inc. | -4.124M |
| Repligen Corp. | 43.10M |
| AC Immune SA | -- |
| Inovio Pharmaceuticals, Inc. | -15.27M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -13.97M |
| Cash from Financing (Quarterly) | 0.733M |
| Free Cash Flow | -74.32M |
| Free Cash Flow Per Share (Quarterly) | 0.0272 |
| Free Cash Flow to Equity (Quarterly) | 11.19M |
| Free Cash Flow to Firm (Quarterly) | 14.43M |
| Free Cash Flow Yield | -4.85% |